» Articles » PMID: 31216380

Mesenchymal Stem Cells: Cell Therapy and Regeneration Potential

Overview
Date 2019 Jun 20
PMID 31216380
Citations 255
Authors
Affiliations
Soon will be listed here.
Abstract

Rapid advances in the isolation of multipotent progenitor cells, routinely called mesenchymal stromal/stem cells (MSCs), from various human tissues and organs have provided impetus to the field of cell therapy and regenerative medicine. The most widely studied sources of MSCs include bone marrow, adipose, muscle, peripheral blood, umbilical cord, placenta, fetal tissue, and amniotic fluid. According to the standard definition of MSCs, these clonal cells adhere to plastic, express cluster of differentiation (CD) markers such as CD73, CD90, and CD105 markers, and can differentiate into adipogenic, chondrogenic, and osteogenic lineages in vitro. However, isolated MSCs have been reported to vary in their potency and self-renewal potential. As a result, the MSCs used for clinical applications often lead to variable or even conflicting results. The lack of uniform characterization methods both in vitro and in vivo also contributes to this confusion. Therefore, the name "MSCs" itself has been increasingly questioned lately. As the use of MSCs is expanding rapidly, there is an increasing need to understand the potential sources and specific potencies of MSCs. This review discusses and compares the characteristics of MSCs and suggests that the variations in their distinctive features are dependent on the source and method of isolation as well as epigenetic changes during maintenance and growth. We also discuss the potential opportunities and challenges of MSC research with the hope to stimulate their use for therapeutic and regenerative medicine.

Citing Articles

Therapeutic potential of total flavonoids of Rhizoma Drynariae: inhibiting adipogenesis and promoting osteogenesis via MAPK/HIF-1α pathway in primary osteoporosis.

Su H, Liu L, Yan Z, Guo W, Huang G, Zhuang R J Orthop Surg Res. 2025; 20(1):260.

PMID: 40069718 PMC: 11895304. DOI: 10.1186/s13018-025-05665-8.


Mesenchymal stromal/stem cells from perinatal sources: biological facts, molecular biomarkers, and therapeutic promises.

Allouh M, Rizvi S, Alamri A, Jimoh Y, Aouda S, Ouda Z Stem Cell Res Ther. 2025; 16(1):127.

PMID: 40055783 PMC: 11889844. DOI: 10.1186/s13287-025-04254-0.


Immunomodulatory effects of mesenchymal stem cell therapy in chronic kidney disease: a literature review.

Li J, Wu M, He L BMC Nephrol. 2025; 26(1):107.

PMID: 40033224 PMC: 11874639. DOI: 10.1186/s12882-025-04029-y.


Molecular roles in membrane receptor signaling pathways and cascade reactions in chondrocytes: a review.

Zhu Y, Zhu J, Wang X, Wang P, Liu R J Mol Histol. 2025; 56(2):94.

PMID: 39988650 DOI: 10.1007/s10735-025-10368-9.


Recent advances in mesenchymal stem cell therapy for multiple sclerosis: clinical applications and challenges.

Sheikhi K, Ghaderi S, Firouzi H, Rahimibarghani S, Shabani E, Afkhami H Front Cell Dev Biol. 2025; 13:1517369.

PMID: 39963155 PMC: 11830822. DOI: 10.3389/fcell.2025.1517369.